Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.28 EUR | -4.90% | -12.09% | -6.57% |
Apr. 10 | Transgene: presents vaccine results at AACR | CF |
Mar. 28 | Transgene CFO Steps Down; Successor Assumes Office | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- One of the major weak points of the company is its financial situation.
- Based on current prices, the company has particularly high valuation levels.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-6.57% | 145M | C+ | ||
-1.71% | 104B | B+ | ||
+2.38% | 97.42B | B+ | ||
+0.79% | 22.2B | B | ||
-17.51% | 21.23B | B+ | ||
-11.11% | 18.33B | A- | ||
-42.83% | 16.35B | A- | ||
-16.31% | 15.06B | B | ||
+4.11% | 13.98B | C+ | ||
+33.82% | 11.66B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- TNG Stock
- Ratings Transgene